EUVIMEDEUVIMED entdecken
Systematische Übersicht

ORAL HEALTH CONSEQUENCES OF SEMAGLUTIDE (GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST) THERAPY: SYSTEMATIC REVIEW WITH EVIDENCE GRADING AND CLINICAL RECOMMENDATIONS

Dr. Jaideep Kour Raina

International Journal of Advanced Research · 31.07.2026 · 14 (07) · 1042-1049

DOI: 10.21474/ijar01/23857 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift International Journal of Advanced Research, online erschienen am 31.07.2026. Verfasst von Dr. Jaideep Kour Raina.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Semaglutide, a long-acting glucagon - like peptide -1 receptor agonist, is among the most rapidly adopted medications globally for management of type 2 diabetes mellitus and obesity. As prescriptions exceeded nine million quarterly in the United States by end-2022, dental clinicians worldwide have observed a distinct pattern of accelerated oral deterioration in users. No systematic review consolidating oral health consequences across all relevant clinical domains has previously appeared in the oral pathology literature.

Methods

A systematic review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 statement. Structured searches were performed in PubMed/MEDLINE, Scopus, Cochrane Library, Web of Science, and the Food and Drug Administration Adverse Event Reporting System (inception to June 2026). All study designs examining semaglutide or glucagon-like peptide-1 receptor agonist therapy in relation to oral health outcomes were eligible. Evidence certainty was rated using the Grading of Recommendations Assessment, Development and Evaluation framework.

Zitieren

APA

Raina, D. J. K. (2026). ORAL HEALTH CONSEQUENCES OF SEMAGLUTIDE (GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST) THERAPY: SYSTEMATIC REVIEW WITH EVIDENCE GRADING AND CLINICAL RECOMMENDATIONS. International Journal of Advanced Research, 14(07), 1042-1049. https://doi.org/10.21474/ijar01/23857

Vancouver

Raina DJK. ORAL HEALTH CONSEQUENCES OF SEMAGLUTIDE (GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST) THERAPY: SYSTEMATIC REVIEW WITH EVIDENCE GRADING AND CLINICAL RECOMMENDATIONS. International Journal of Advanced Research. 2026;14(07):1042-1049. doi:10.21474/ijar01/23857

BibTeX
@article{Raina2026,
  author = {Raina, Dr. Jaideep Kour},
  title = {ORAL HEALTH CONSEQUENCES OF SEMAGLUTIDE (GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST) THERAPY: SYSTEMATIC REVIEW WITH EVIDENCE GRADING AND CLINICAL RECOMMENDATIONS},
  journal = {International Journal of Advanced Research},
  year = {2026},
  volume = {14},
  number = {07},
  pages = {1042--1049},
  doi = {10.21474/ijar01/23857}
}
Kostenlos starten →